Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more
Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 read more
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors read more
Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 read more
There are currently no events scheduled.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|